

## CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be  
a) a guide for reporting for authors of RCTs,  
b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.

Items with Roman numerals (I, II, III, IV etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red \*.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF \_AND\_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions

J Med Internet Res 2011;13(4):e126

URL: <http://www.jmir.org/2011/4/e126/>

doi: 10.2196/jmir.1923

PMID: 22209829

\* Required

**Your name \***

First Last

Jeffrey Lambert

**Primary Affiliation (short), City, Country \***

University of Toronto, Toronto, Canada

University of Exeter, Exeter, UK

**Your e-mail address \***

abc@gmail.com

j.d.lambert@exeter.ac.uk

**Title of your manuscript \***

Provide the (draft) title of your manuscript.

A pilot randomized controlled trial of an administratively supported web-based intervention using behavioral activation and physical activity for adults with depression: The eMotion study.

**Name of your App/Software/Intervention \***

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

eMotion

**Evaluated Version (if any)**

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

V1

**Language(s) \***

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

English

**URL of your Intervention Website or App \***

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

Your answer

**URL of an image/screenshot (optional)**

Your answer

**Accessibility \***

Can an enduser access the intervention presently?

- access is free and open
- access only for special usergroups, not open
- access is open to everyone, but requires payment/subscription/in-app purchases
- app/intervention no longer accessible
- Other:

**Primary Medical Indication/Disease/Condition \***

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

Depression

**Primary Outcomes measured in trial \***

comma-separated list of primary outcomes reported in the trial

Depression (PHQ-8)

**Secondary/other outcomes**

Are there any other outcomes the intervention is expected to affect?

Objective physical activity, self reported physical activity, Anxiety

**Recommended "Dose" \***

What do the instructions for users say on how often the app should be used?

- Approximately Daily
- Approximately Weekly
- Approximately Monthly
- Approximately Yearly
- "as needed"
- Other:

**Approx. Percentage of Users (starters) still using the app as recommended after 3 months \***

- unknown / not evaluated
- 0-10%
- 11-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71-80%
- 81-90%
- 91-100%
- Other:

**Overall, was the app/intervention effective? \***

- yes: all primary outcomes were significantly better in intervention group vs control
- partly: SOME primary outcomes were significantly better in intervention group vs control
- no statistically significant difference between control and intervention
- potentially harmful: control was significantly better than intervention in one or more outcomes
- inconclusive: more research is needed
- Other: This is a pilot study. Exploratory analysis found an effect in favour

**Article Preparation Status/Stage \***

At which stage in your article preparation are you currently (at the time you fill in this form)

- not submitted yet - in early draft status
- not submitted yet - in late draft status, just before submission
- submitted to a journal but not reviewed yet
- submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
- published
- Other:

**Journal \***

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)
- JMIR mHealth and UHealth
- JMIR Serious Games
- JMIR Mental Health
- JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- Other:

**Is this a full powered effectiveness trial or a pilot/feasibility trial? \***

- Pilot/feasibility
- Fully powered

**Manuscript tracking number \***

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

- no ms number (yet) / not (yet) submitted to / published in JMIR
- Other:

**TITLE AND ABSTRACT**

**1a) TITLE: Identification as a randomized trial in the title**

**1a) Does your paper address CONSORT item 1a? \***

I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

- yes
- Other:

**1a-i) Identify the mode of delivery in the title**

Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.

subitem not at all important      essential

**Does your paper address subitem 1a-i? \***

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"web-based"

**1a-ii) Non-web-based components or important co-interventions in title**

Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").

subitem not at all important      essential

**Does your paper address subitem 1a-ii?**

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

**1a-iii) Primary condition or target group in the title**

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes")  
Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

subitem not at all important      essential

**Does your paper address subitem 1a-iii? \***

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"for adults with depression"

**1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions**

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

**1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT**

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important      essential

**Does your paper address subitem 1b-i)? \***

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

eMotion is an administratively supported weekly modular programme aiming to help people use key behavior change techniques (e.g., graded tasks, action planning and self-monitoring) to re-engage in routine, pleasurable or necessary activities, with a focus on physical activities. Feasibility data was collected which included: recruitment and trial retention rates, the fidelity of intervention delivery, receipt and enactment, and the acceptability of the intervention and data collection procedures."

**1b-ii) Level of human involvement in the METHODS section of the ABSTRACT**

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important      essential

**Does your paper address subitem 1b-ii)?**

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"administratively supported"

**1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT**

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important      essential

**Does your paper address subitem 1b-iii?**

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Data was collected for the primary (depression) and secondary outcomes (e.g. anxiety, PA, fidelity and client satisfaction) at baseline and two months post randomization using self-reported online questionnaires and accelerometers."

**1b-iv) RESULTS section in abstract must contain use data**

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important      essential

**Does your paper address subitem 1b-iv?**

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Within the intervention group, the median number of logins, modules accessed and total minutes spent on eMotion was 3 (IQR = 2.0 to 8.0), 3 (IQR = 2.0 to 5.0) and 41.3 (IQR = 18.9 to 90.4) respectively.

**1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials**

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important      essential

**Does your paper address subitem 1b-v?**

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Exploratory data showed that PHQ-8 levels were reduced more for the intervention group than the control group at two months post randomization (Adjusted Mean Difference: -3.6 (95% CI: -6.1 to -1.1))."

**INTRODUCTION**

**2a) In INTRODUCTION: Scientific background and explanation of rationale**

**2a-i) Problem and the type of system/solution**

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

subitem not at all important      essential



**Does your paper address subitem 2a-i? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Depression has a significant detrimental impact on individuals and their families, as well as increased utilisation of health services, and reduced productivity at work leading to considerable economic costs" "Physical activity (PA) has also been shown to be effective in treating (Cooney et al., 2013) and preventing (Mammen & Faulkner, 2013) depression, and is often cited by patients as their preferred treatment option (Searle et al., 2011; Ussher, Stanbury, Cheeseman, & Faulkner, 2007)." "Web-based interventions could provide a useful way of overcoming these limitations by delivering such interventions outside of existing services, recruiting directly from the community and standardising fidelity (Lambert, Greaves, Farrand, Cross, et al., 2017; Watkins et al., 2016)."

**2a-ii) Scientific background, rationale: What is known about the (type of) system**

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

subitem not at all important      essential

**Does your paper address subitem 2a-ii? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"There is a paucity of studies that have attempted to deliver web-based interventions promoting PA for depression (Carlbring et al., 2013; Nyström et al., 2017; Rosenbaum, Newby, Steel, Andrews, & Ward, 2015; Soucy, Provencher, Fortier, & McFadden, 2017), and no studies have explored the feasibility of delivering a web based intervention combining BA and PA for people with depression. "

**2b) In INTRODUCTION: Specific objectives or hypotheses**

**Does your paper address CONSORT subitem 2b? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The purpose of the present study is to examine the feasibility of delivering an online intervention (eMotion) combining PA with BA to people for depression, and to explore its effects on depression and PA."

**METHODS**

**3a) Description of trial design (such as parallel, factorial) including allocation ratio**

**Does your paper address CONSORT subitem 3a? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The eMotion trial was a two-arm, individually randomized, parallel group pilot RCT with a nested process evaluation"



3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The eMotion trial provided 'minimal contact' administrative support (Farrand & Woodford, 2013) at week two of the intervention to provide the participant with a rationale for the use of self-help materials and check-ins related to progress (but with no focus on any clinical or behavior change issues). This support was initially intended to be provided by an independent 'supporter'. However due to resource issues, this support was provided by the lead author. "

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-ii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

subitem not at all important      essential

Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes

4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

subitem not at all important      essential

Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"were computer literate"



**4a-ii) Open vs. closed, web-based vs. face-to-face assessments:**

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

subitem not at all important      essential

**Does your paper address subitem 4a-ii? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Eligible adults were recruited from the community via advertisements in weekly newspapers, social media (e.g. Facebook support groups, Twitter) and through banners on websites relating to mental health problems."

**4a-iii) Information giving during recruitment**

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

subitem not at all important      essential

**Does your paper address subitem 4a-iii?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"After contacting the lead author by phone or email, potential participants were sent the participant information sheet (PIS), consent form, and a link to the online screening questionnaire, via email. At this point, they were informed that they could withdraw from the study at any time without consequence or being obliged to provide a reason. Once participants read the PIS, they were asked to complete the online consent form followed by a screening questionnaire used by the lead author to assess participant eligibility. After screening, the lead author contacted the participant via phone to clarify the study procedures and provided instructions for wearing the wrist-worn accelerometers sent by post. The participant was instructed to wear for the accelerometer for seven days and return it in a pre-stamped and addressed envelope. However, participant refusal to wear an accelerometer did not preclude randomization. Further baseline measures were then administered via a separate online questionnaire. Participants were not paid for their involvement in the study."

**4b) Settings and locations where the data were collected**

**Does your paper address CONSORT subitem 4b? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes



**4b-i) Report if outcomes were (self-)assessed through online questionnaires**

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

subitem not at all important      essential

**Does your paper address subitem 4b-i? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"delivered at screening and two months post-randomization using an online self-completed version of the questionnaire"

**4b-ii) Report how institutional affiliations are displayed**

Report how institutional affiliations are displayed to potential participants (on ehealth media), as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item - describe only if this may bias results)

subitem not at all important      essential

**Does your paper address subitem 4b-ii?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

**5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered**

**5-i) Mention names, credential, affiliations of the developers, sponsors, and owners**

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

subitem not at all important      essential

**Does your paper address subitem 5-i?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The content for eMotion was developed by the study authors (\*\*, \*\*, \*\*, \*\* & \*\*). The Living Life to the Full (LLTF) online platform was used to host the intervention."

**5-ii) Describe the history/development process**

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

subitem not at all important      essential



**Does your paper address subitem 5-ii?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"eMotion was adapted from the BAcPac intervention (Farrand et al., 2014; Pentecost et al., 2015), using the Centre for eHealth Research and Disease Management (CeHReS) roadmap (van Gemert-Pijnen et al., 2011). The CeHReS roadmap is intended to help the planning, coordination and execution of the participatory development process of eHealth. In eMotion, this involved using patient public involvement, usability testing and a structured literature search. A full description of the eMotion intervention and its developmental process is provided elsewhere (Lambert, Greaves, Farrand, Haase, & Taylor, 2017)."

**5-iii) Revisions and updating**

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

subitem not at all important      essential

**Does your paper address subitem 5-iii?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

**5-iv) Quality assurance methods**

Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

subitem not at all important      essential

**Does your paper address subitem 5-iv?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

**5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used**

Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

subitem not at all important      essential

**Does your paper address subitem 5-v?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: Found in intervention description and published paper on interventiomn development (Lambert et al., 2017)



**5-vi) Digital preservation**

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, [webcitation.org](http://webcitation.org), and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

subitem not at all important      essential

**Does your paper address subitem 5-vi?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Screenshots provided in Lambert et al., (2017)

**5-vii) Access**

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

subitem not at all important      essential

**Does your paper address subitem 5-vii? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Through a series of steps delivered in a week by week modular fashion (table 1), eMotion teaches people how to re-establish daily routines, increasing activities that provide positive reinforcement whilst reducing negative reinforcement. eMotion comprises 13 modules (1 introduction module, 8 weekly modules, 1 generic problem-solving module and 3 unlockable modules) consisting of visual content with an audio voiceover triggered when each slide opens. Printable, interactive worksheets and emails are also included, with links to the slides to allow downloading to a personal computer or another device (e.g. tablet or smartphone). Automated reminder emails are also sent once a week by the eMotion programme following registration."

**5-viii) Mode of delivery, features/functionality/components of the intervention and comparator, and the theoretical framework**

Describe mode of delivery, features/functionality/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1], "whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

subitem not at all important      essential

**Does your paper address subitem 5-viii? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The eMotion intervention is a web-based course that provides people with access to an evidence-based treatment based on BA with added PA promotion. People with depression commonly reduce activities which they perceive as burdensome, making less effort to do things they may have previously enjoyed. By reducing such activities, people with depression experience temporary relief which then negatively reinforces the likelihood of avoiding further activities. However, avoiding such activities has a long term cost, as it reduces the opportunity for positive reinforcement which occurs when people engage in social and personal activities which bring them pleasure and achievement. PA is an example of such an activity which people with depression often avoid but has the potential to provide additional anti-depressive benefits as well as added health benefits. "

**5-ix) Describe use parameters**

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

subitem not at all important      essential

**Does your paper address subitem 5-ix?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Key content relating to the rationale of BA is front loaded in the introduction, week 1 and week 2. The remaining weekly modules (weeks 3 to 8) are shorter and designed to support people to review and update their plans. The intervention supports 'effective engagement' and self-regulation by encouraging people to review their plans weekly, irrespective of whether or not they continue to log in (e.g. by using their own diaries). "

**5-x) Clarify the level of human involvement**

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

subitem not at all important      essential

**Does your paper address subitem 5-x?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"brief administrative/motivational support via a 10 minute phone call was provided at week 2."

**5-xi) Report any prompts/reminders used**

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

subitem not at all important      essential

**Does your paper address subitem 5-xi? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Automated reminder emails are also sent once a week by the eMotion programme following registration."

**5-xii) Describe any co-interventions (incl. training/support)**

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

subitem not at all important      essential

**Does your paper address subitem 5-xii? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

**6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed**

**Does your paper address CONSORT subitem 6a? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes

**6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed**

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

subitem not at all important      essential

**Does your paper address subitem 6a-i?**

Copy and paste relevant sections from manuscript text

"The PHQ-8 has been shown to have good validity, reliability, sensitivity and specificity (Kroenke et al., 2009) and been used in previous web-based intervention studies of low mood and depression (Baumeister et al., 2014; Richards & Richardson, 2012)"

**6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored**

Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

subitem not at all important      essential

**Does your paper address subitem 6a-ii?**

Copy and paste relevant sections from manuscript text

"Delivery fidelity was assessed using website usage statistics from the online intervention database. This database provided individual level data about whether the participant registered for eMotion, modules accessed and the total time spent on each module. Participant receipt and enactment of the intended intervention processes were measured using online questionnaires. For fidelity of receipt, two conceptual approaches were used, The first focused on participants' understanding of how emotions, behaviors, thoughts and physical feelings affect each other to maintain depression over time. A single item was used based on questions used in a previous study (Brawley, Arbour-Nicitopoulos, & Martin Ginis, 2013). The item employed a five-point Likert response scale (Strongly Agree to Strongly Disagree) assessing participant agreement with the following statement: "I understand how emotions, behaviors, thoughts and physical feelings affect each other to maintain depression over time." A second measure of receipt assessed participants' perceived ability to use the intended behavior change techniques (BCTs). This was assessed by asking participants to rate their confidence in using specific BCTs (i.e. identification of suitable activities, grading activities for ease of use, planning and dealing with setbacks) in the last two months on a scale from 1 (not at all confident) to 10 (very confident). This measure was adapted from measures of confidence used in the ProActive trial (Hardeman et al., 2008). Finally, to assess enactment, we asked participants if they had used specific BCTs relating to behavioral activation (BA) in the last two months using a binary scale (yes/no). This measure was adapted from similar measures of BCT usage that showed that enactment was significantly associated with weight loss, providing initial evidence of the validity of this type of measure (Hankonen et al., 2014)."

**6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained**

Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).

subitem not at all important      essential

**Does your paper address subitem 6a-iii?**

Copy and paste relevant sections from manuscript text

"The Client Satisfaction Questionnaire – Short Form (CSQ-SF) is a 4 item measure to assess participant satisfaction regarding their use of eMotion two months post-randomization (given to intervention participants only). This measure was administered using an online questionnaire and has been used to assess treatment satisfaction in web-based studies of other interventions for depression (Williams et al., 2013)."

**6b) Any changes to trial outcomes after the trial commenced, with reasons**

**Does your paper address CONSORT subitem 6b? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

**7a) How sample size was determined**

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed



**7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size**

Describe whether and how expected attrition was taken into account when calculating the sample size.

subitem not at all important      essential

**Does your paper address subitem 7a-i?**

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Due to the pilot nature of the study, no formal sample size calculations were conducted. However, to ensure a suitably reliable estimate of the standard deviations to power a future trial with 90% power, at least 15 people per arm are recommended if the expected effect size lies between 0.3 and 0.7 (Whitehead, Julious, Cooper, & Campbell, 2015). A previous meta-analysis of computer-based psychological treatments for depression reported a moderate effect size (0.56) and a drop-out rate of 57% (Richards & Richardson, 2012). As such, a target sample size of 62 (accounting for a possible attrition rate of 50%) to ensure at least 15 people per arm at follow up was adopted."

**7b) When applicable, explanation of any interim analyses and stopping guidelines**

**Does your paper address CONSORT subitem 7b? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

**8a) Method used to generate the random allocation sequence**

NPT: When applicable, how care providers were allocated to each trial group

**Does your paper address CONSORT subitem 8a? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Once participants completed the baseline assessment, they were randomly allocated to either the intervention or control group using simple randomization at the individual level in a 1:1 ratio and an online randomization service (Sealed Envelope Ltd. 2016). Personal details were anonymized through the use of participant numbers which were entered into the website by the lead author in a consecutive manner (in the order of completed baseline assessment), and the randomization service allocated them to either group A (eMotion) or group B (waiting list)."

**8b) Type of randomisation; details of any restriction (such as blocking and block size)**

**Does your paper address CONSORT subitem 8b? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Once participants completed the baseline assessment, they were randomly allocated to either the intervention or control group using simple randomization at the individual level in a 1:1 ratio"

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"online randomization service (Sealed Envelope Ltd. 2016)"

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

subitem not at all important      essential

Does your paper address subitem 11a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Due to limited resources for the study, the lead author was not blinded to which condition each participant was allocated following randomization. Due to the nature of the intervention, it was also impossible to blind participants to group allocation. However, as outcome measures were taken using online self-report surveys, there was a reduced chance of the lead author influencing the participant's responses, or for the lead author to misinterpret responses or introduce subjective bias into recorded observations (Edwards, 2010)."

11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-i) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".

subitem not at all important      essential

**Does your paper address subitem 11 a-ii?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Due to limited resources for the study, the lead author was not blinded to which condition each participant was allocated following randomization. Due to the nature of the intervention, it was also impossible to blind participants to group allocation. However, as outcome measures were taken using online self-report surveys, there was a reduced chance of the lead author influencing the participant's responses, or for the lead author to misinterpret responses or introduce subjective bias into recorded observations (Edwards, 2010)."

**11b) If relevant, description of the similarity of interventions**

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

**Does your paper address CONSORT subitem 11b? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

**12a) Statistical methods used to compare groups for primary and secondary outcomes**

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

**Does your paper address CONSORT subitem 12a? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Quantitative methods were used to explore: the recruitment and attrition rates of trial participants, the feasibility of data collection and study procedures, baseline data (including levels of PA and baseline differences between groups and between dropouts), and fidelity of delivery. Descriptive statistics were produced for all outcomes by trial arm at baseline and two-month follow-up. All quantitative analyses were conducted using Stata SE statistical software release 14 (StataCorp. 2015; College Station, TX). No formal hypothesis-testing relating to primary outcomes was planned as this was a pilot study. However, descriptive statistics were used to assess recruitment and retention rates, and baseline PA levels. Baseline demographic and clinical characteristics were presented descriptively as proportions or as means with standard deviations. Two types of exploratory analysis of the primary outcome for the main trial (PHQ-8) were conducted: 1) linear regression models to report changes in depression with 95% confidence intervals around the between-group mean difference and 2) logistic regression models which dichotomised the primary outcome to reflect clinically meaningful change (a reduction to below ten on the PHQ-8 indicates that the person may no longer qualify for major depression (Kroenke et al., 2009))."

**12a-i) Imputation techniques to deal with attrition / missing values**

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

subitem not at all important      essential

**Does your paper address subitem 12a-i? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The analyses were conducted on an intention-to-treat basis with complete data only, which included those who began treatment and provided follow-up data regardless of treatment compliance. Missing data were not imputed with data from participants who provided data at both time points analysed."

**12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses**

**Does your paper address CONSORT subitem 12b? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Similar analyses were conducted for anxiety, and objective and self-reported PA. We conducted sensitivity analyses linear regression models to examine the effects of receiving psychological therapies, as well as any substantial differences in baseline characteristics on the findings."

**X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)**

**X26-i) Comment on ethics committee approval**

subitem not at all important      essential

**Does your paper address subitem X26-i?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This study was approved by the University of Exeter Sports and Health Sciences Research Ethics Committee (AM160316-21 151021/B/03)."

**x26-ii) Outline informed consent procedures**

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

subitem not at all important      essential

**Does your paper address subitem X26-ii?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Once participants read the PIS, they were asked to complete the online consent form (indicating consent using a checkbox) followed by a screening questionnaire used by the lead author to assess participant eligibility."

**X26-iii) Safety and security procedures**

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

subitem not at all important      essential

**Does your paper address subitem X26-iii?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"One possible ethical issue in this study was suicide risk in people experiencing depression. As this was a research study on a non-clinical sample, all participants were advised on the PIS that the study was not a clinical or NHS treatment and that the University and researchers could not take clinical responsibility for the treatment of any conditions they might have including depression. They were also signposted to other appropriate resources in case they wished to seek formal treatment. If, at any point in the study (e.g. whilst on the phone to a researcher during screening or after inclusion), participants indicated suicidal intent, the University of Exeter Mood Disorders Suicide Risk Protocol was invoked."

**RESULTS**

**13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome**

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

**Does your paper address CONSORT subitem 13a? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A total of 183 people responded to the adverts, with 100 completing screening for eligibility (Figure 1). Of the 183 individuals who initially inquired about the study 100 were still interested screened for eligibility and 62 (34% of those initially enquiring (95% CI: 27 to 41%) and 62% of those who were screened (95% CI: 52 to 71%)) were eligible for inclusion and randomized into the trial between May 2016 and February 2017 (32 eMotion, 30 control)."

**13b) For each group, losses and exclusions after randomisation, together with reasons**

**Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Overall attrition (in relation to the planned main trial primary outcome (PHQ-8) at two months post-randomization was 12 people (19%; 95% CI: 11 to 31%). Of those randomized, 58 (94%) participants provided complete secondary outcome baseline measurements (e.g. GAD7, IPAQ-SF) and 52 (84%) provided usable accelerometer data at baseline. At two-month follow-up, 50 (81% of those randomized (95% CI: 71 to 91 %) provided PHQ-8 (and other survey data) and 24 (39% of those randomized (95% CI: 27 to 52%) provided valid accelerometer data (with >10 hours data for at least 3 weekdays and one weekend day). Mean weekend days of wear time for the accelerometers was 2.0 (SD = 0.2) at baseline and 1.9 (SD = 0.3) at two-month post-randomization. Mean weekday days of wear time for the accelerometers was 4.8 (SD = 0.3) at baseline and 4.6 (SD = 0.9) at two months post randomization. Only 47 (76%) and 33 (53%) participants provided valid IPAQ-SF data at baseline and two months post-randomization respectively. This lack of usable IPAQ-SF data was due to people providing invalid responses to the IPAQ-SF."

**13b-i) Attrition diagram**

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

subitem not at all important      essential

**Does your paper address subitem 13b-i?**

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

**14a) Dates defining the periods of recruitment and follow-up**

**Does your paper address CONSORT subitem 14a? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Reported in 'fidelity' section

**14a-i) Indicate if critical "secular events" fell into the study period**

Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"

subitem not at all important      essential

**Does your paper address subitem 14a-i?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

**14b) Why the trial ended or was stopped (early)**

**Does your paper address CONSORT subitem 14b? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

**15) A table showing baseline demographic and clinical characteristics for each group**

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

**Does your paper address CONSORT subitem 15? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Table 2

**15-i) Report demographics associated with digital divide issues**

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

subitem not at all important      essential

**Does your paper address subitem 15-i? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Table 2

**16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups**

**16-i) Report multiple "denominators" and provide definitions**

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1]. e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

subitem not at all important      essential

**Does your paper address subitem 16-i? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Table 3/4

**16-ii) Primary analysis should be intent-to-treat**

Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).

subitem not at all important      essential

**Does your paper address subitem 16-ii?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Analysis were intend to treat with complete data only

**17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)**

**Does your paper address CONSORT subitem 17a? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Exploratory analyses (table 4) showed that at two months post randomization, the intervention group had a larger reduction in depressive symptoms than the control group (Adjusted Mean Diff -3.6, 95% CI: -6.1 to -1.1)."

**17a-i) Presentation of process outcomes such as metrics of use and intensity of use**

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

subitem not at all important      essential

**Does your paper address subitem 17a-i?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"In total, 28 (90%) of the 32 intervention participants registered for eMotion and clicked on the introduction module. The median number of logins, modules accessed and total minutes spent on eMotion was 3 (IQR = 2.0 to 8.0), 3 (IQR = 2.0 to 5.0) and 41.3 (IQR = 18.9 to 90.4) respectively. 61% of participants completed at least the introduction, week 1 and week 2 and 29% of participants completed up to at least week 4. Only one participant used every module. At two months post-randomization, participants randomized to the eMotion group reported a significant difference, compared to the control group, in levels of understanding about how thoughts, feelings and behaviors affect mood (Adjusted Mean Diff 0.5, 95% CI: -0.0 to -1.0). Significant differences were also found for confidence to identify (Adjusted Mean Diff 1.4, 95% CI: 0.0 to 2.8), select (Mean Diff 1.3, 95% CI: -0.02 to 2.6) and plan (Mean Diff 1.8, 95% CI: 0.5 to 3.1) achievable activities to improve mood as well as confidence to deal with setbacks (Mean Diff 1.5, 95% CI: 0.2 to 2.7). Those who were randomized to the eMotion group and who endorsed 'no' on the enactment questionnaires at baseline were significantly more likely to select (N = 25; OR: 10, 95% CI: 1.6 to 62.7) and plan (N = 33; OR: 10.3, 95% CI: 2.0 to 52.6) activities to improve their mood at two month follow up."

**17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended**



**Does your paper address CONSORT subitem 17b? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"In the intervention group, 56% (14/25) of depression scores went below the threshold of 10 on the PHQ-8, compared to 28% (7/25) in the control group (OR 3.3, 95% CI: 1.0 to 10.6)."

**18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory**

**Does your paper address CONSORT subitem 18? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"When receipt of other psychological therapies was entered into the regression analysis as a covariate, the impact of co-treatment was not significant, and the intervention group still had a higher reduction in depressive symptoms than the control group (Mean Diff -3.3, 95% CI: -5.9 to -0.7). Other baseline covariates (age, gender, employment, education level, anti-depressant usage) that may have influenced depression scores were also entered in the regression model together. Findings indicated that none of these variables had a significant covariate effect on depression scores and the residual difference between groups was still significant (Mean Diff -3.1, 95% CI: -5.7 to -0.5). Within the intervention group, linear regression analyses revealed no significant relationships between numbers of modules accessed, number of logins or total minutes spent on the website with depression outcomes. The pattern of change scores within each group is shown in figure 2."

**18-i) Subgroup analysis of comparing only users**

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

subitem not at all important      essential

**Does your paper address subitem 18-i?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

**19) All important harms or unintended effects in each group**

(for specific guidance see CONSORT for harms)

**Does your paper address CONSORT subitem 19? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No harms or unintended effects observed

**19-i) Include privacy breaches, technical problems**

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

subitem not at all important      essential

**Does your paper address subitem 19-i?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No privacy breaches, technical problems observed

**19-ii) Include qualitative feedback from participants or observations from staff/researchers**

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

subitem not at all important      essential

**Does your paper address subitem 19-ii?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Qualitative data gathered, but will be reported elsewhere

**DISCUSSION**

**22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence**

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

**22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)**

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

subitem not at all important      essential

**Does your paper address subitem 22-i? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The present study examined the feasibility of conducting an RCT of the eMotion intervention. We successfully recruited a less active population with elevated depressive symptoms. The trial also had acceptable attrition rates concerning the primary outcome at two months"

**22-ii) Highlight unanswered new questions, suggest future research**

Highlight unanswered new questions, suggest future research.

subitem not at all important      essential

**Does your paper address subitem 22-ii?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Reported in discussion "Implications for future research" section

**20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses**

**20-i) Typical limitations in ehealth trials**

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

subitem not at all important      essential

**Does your paper address subitem 20-i? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Reported in discussion "Strengths and limitations" section

**21) Generalisability (external validity, applicability) of the trial findings**

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

**21-i) Generalizability to other populations**

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

subitem not at all important      essential

**Does your paper address subitem 21-i?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Reported in discussion "Relationship to other literature" section

**21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting**

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

subitem not at all important      essential

**Does your paper address subitem 21-ii?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Reported in discussion "Strengths and limitations" section

**OTHER INFORMATION**

**23) Registration number and name of trial registry**

**Does your paper address CONSORT subitem 23? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

ClinicalTrials.gov NC-T03084055

**24) Where the full trial protocol can be accessed, if available**

**Does your paper address CONSORT subitem 24? \***

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

**25) Sources of funding and other support (such as supply of drugs), role of funders**

**Does your paper address CONSORT subitem 25? \***

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In acknowledgements section

**X27) Conflicts of Interest (not a CONSORT item)**

**X27-i) State the relation of the study team towards the system being evaluated**

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

subitem not at all important      essential

**Does your paper address subitem X27-i?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No conflicts of interest

**About the CONSORT EHEALTH checklist**



As a result of using this checklist, did you make changes in your manuscript? \*

- yes, major changes  
 yes, minor changes  
 no

What were the most important changes you made as a result of using this checklist?

Adding further detail around participant flow

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript \*

Approx 2 hours

As a result of using this checklist, do you think your manuscript has improved? \*

- yes  
 no  
 Other:

Would you like to become involved in the CONSORT EHEALTH group?

This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document

- yes  
 no  
 Other:

Any other comments or questions on CONSORT EHEALTH

Your answer

**STOP - Save this form as PDF before you click submit** ▼

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

**Final step: Click submit!** ▼

Click submit so we have your answers in our database!

SUBMIT

Never submit passwords through Google Forms

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Additional Terms

Google Forms